New drug JYP0015 targets RAS-Mutant cancers in phase 2 trial
Disease control
Recruiting now
This study tests a new drug called JYP0015 in adults with advanced solid tumors that have a specific genetic change called RAS mutation. The goal is to see if the drug is safe and can shrink tumors. About 210 people with pancreatic, lung, or colorectal cancer will take part.
Phase: PHASE2 • Sponsor: Guangzhou JOYO Pharma Co., Ltd • Aim: Disease control
Last updated May 11, 2026 20:50 UTC